person · Reporting owner

Sullivan Christopher Ryan

Disclosed activity across 1 company

Tapewire entity: 21663
SEC CIK: 0001810417

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalo Therapeutics, Inc.AVTX · Entity 4936	Chief Financial Officer	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalo Therapeutics, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,900	Ending reported balance After 2026-09-16 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-16 · Exercise / conversion · Acquired 12,394 · Balance 52,294 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Row 2 · 2026-09-16 · Sale · Disposed 12,394 · Balance 39,900 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F2: The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.88 · Expires 2034-08-13	Direct	83,848	Reported balance After 2026-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-16 · Exercise / conversion · Disposed 12,394 · Balance 83,848 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F3: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.

F2: The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F3: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 10, 2021 Filed Dec 14, 2021 22:17 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	PurchaseCommon Stock	955	$1.57	$1,499.35	Disclosure SEC source: 0001879785-21-000039 · edgar.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,004 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document
January 26, 2021 Filed Jan 28, 2021 21:08 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (Right to Buy) · Derivative	110,000	$0.00 Strike: $3.32	$0.00	Disclosure SEC source: 0001192482-21-000120 · edgar.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document
December 10, 2020 Filed Dec 14, 2020 21:12 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	PurchaseCommon Stock	5,095	$2.28	$11,606.41	Disclosure SEC source: 0001192482-20-000818 · edgar.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,049 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document
June 10, 2020 Filed Jun 12, 2020 01:08 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	PurchaseCommon Stock	2,954	$2.28	$6,729.21	Disclosure SEC source: 0001192482-20-000486 · edgar.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,954 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.